EMulate Therapeutics, Inc. (EMTx) announces the acceptance of a publication of its pre-clinical animal model, testing the effect of its ulRFE® paclitaxel (A1A) signal against a DIPG tumor cell line.

Please provide your email address to receive an email when new articles are posted on . Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse ...

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Modeyso for patients with H3 K27M-mutant diffuse midline glioma. The therapy showed an overall ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

DUBLIN, Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical ...

HOUSTON, Texas (KTRK) -- Six months ago, we told you about a young woman who was diagnosed with a deadly brain tumor only found in children. She has been on a journey with Houston Methodist Hospital ...